Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling.
gene panel analysis
primary immune deficiencies (PID)
reanalysis approach
single nucleotide variant analysis
small INDELs
structural variation analysis
whole exome sequencing
whole genome sequencing (WGS)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
03
2022
accepted:
13
05
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
Knowledge of the genetic variation underlying Primary Immune Deficiency (PID) is increasing. Reanalysis of genome-wide sequencing data from undiagnosed patients with suspected PID may improve the diagnostic rate. We included patients monitored at the Department of Infectious Diseases or the Child and Adolescent Department, Rigshospitalet, Denmark, for a suspected PID, who had been analysed previously using a targeted PID gene panel (457 PID-related genes) on whole exome- (WES) or whole genome sequencing (WGS) data. A literature review was performed to extend the PID gene panel used for reanalysis of single nucleotide variation (SNV) and small indels. Structural variant (SV) calling was added on WGS data. Genetic data from 94 patients (86 adults) including 36 WES and 58 WGS was reanalysed a median of 23 months after the initial analysis. The extended gene panel included 208 additional PID-related genes. Genetic reanalysis led to a small increase in the proportion of patients with new suspicious PID related variants of uncertain significance (VUS). The proportion of patients with a causal genetic diagnosis was constant. In total, five patients (5%, including three WES and two WGS) had a new suspicious PID VUS identified due to reanalysis. Among these, two patients had a variant added due to the expansion of the PID gene panel, and three patients had a variant reclassified to a VUS in a gene included in the initial PID gene panel. The total proportion of patients with PID related VUS, likely pathogenic, and pathogenic variants increased from 43 (46%) to 47 (50%), as one patient had a VUS detected in both initial- and reanalysis. In addition, we detected new suspicious SNVs and SVs of uncertain significance in PID candidate genes with unknown inheritance and/or as heterozygous variants in genes with autosomal recessive inheritance in 8 patients. These data indicate a possible diagnostic gain of reassessing WES/WGS data from patients with suspected PID. Reasons for the possible gain included improved knowledge of genotype-phenotype correlation, expanding the gene panel, and adding SV analyses. Future studies of genotype-phenotype correlations may provide additional knowledge on the impact of the new suspicious VUSs.
Sections du résumé
Background
Knowledge of the genetic variation underlying Primary Immune Deficiency (PID) is increasing. Reanalysis of genome-wide sequencing data from undiagnosed patients with suspected PID may improve the diagnostic rate.
Methods
We included patients monitored at the Department of Infectious Diseases or the Child and Adolescent Department, Rigshospitalet, Denmark, for a suspected PID, who had been analysed previously using a targeted PID gene panel (457 PID-related genes) on whole exome- (WES) or whole genome sequencing (WGS) data. A literature review was performed to extend the PID gene panel used for reanalysis of single nucleotide variation (SNV) and small indels. Structural variant (SV) calling was added on WGS data.
Results
Genetic data from 94 patients (86 adults) including 36 WES and 58 WGS was reanalysed a median of 23 months after the initial analysis. The extended gene panel included 208 additional PID-related genes. Genetic reanalysis led to a small increase in the proportion of patients with new suspicious PID related variants of uncertain significance (VUS). The proportion of patients with a causal genetic diagnosis was constant. In total, five patients (5%, including three WES and two WGS) had a new suspicious PID VUS identified due to reanalysis. Among these, two patients had a variant added due to the expansion of the PID gene panel, and three patients had a variant reclassified to a VUS in a gene included in the initial PID gene panel. The total proportion of patients with PID related VUS, likely pathogenic, and pathogenic variants increased from 43 (46%) to 47 (50%), as one patient had a VUS detected in both initial- and reanalysis. In addition, we detected new suspicious SNVs and SVs of uncertain significance in PID candidate genes with unknown inheritance and/or as heterozygous variants in genes with autosomal recessive inheritance in 8 patients.
Conclusion
These data indicate a possible diagnostic gain of reassessing WES/WGS data from patients with suspected PID. Reasons for the possible gain included improved knowledge of genotype-phenotype correlation, expanding the gene panel, and adding SV analyses. Future studies of genotype-phenotype correlations may provide additional knowledge on the impact of the new suspicious VUSs.
Identifiants
pubmed: 35874679
doi: 10.3389/fimmu.2022.906328
pmc: PMC9302041
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
906328Informations de copyright
Copyright © 2022 Mørup, Nazaryan-Petersen, Gabrielaite, Reekie, Marquart, Hartling, Marvig, Katzenstein, Masmas, Lundgren, Murray, Helleberg and Borgwardt.
Déclaration de conflit d'intérêts
TK has participated in advisory boards for Gilead Sciences, GlaxoSmithKline/ViiV and MSD. TK has received fees for teaching from Takeda and CSL Behring, and a research grant from Gilead Sciences. MH has participated in advisory boards for AstraZeneca, Gilead Sciences, GlaxoSmithKline/ViiV, MSD, Roche, and Sobi. MH has received fees for teaching from Gilead Sciences and GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Genet Med. 2018 Oct;20(10):1216-1223
pubmed: 29323667
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78
pubmed: 26371839
Mol Diagn Ther. 2021 Sep;25(5):529-536
pubmed: 34283395
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
J Clin Immunol. 2017 Jul;37(5):452-460
pubmed: 28523402
Bioinformatics. 2018 Dec 15;34(24):4307-4309
pubmed: 30535305
J Clin Immunol. 2021 Apr;41(3):666-679
pubmed: 33598806
Genome Res. 2011 Jun;21(6):974-84
pubmed: 21324876
J Allergy Clin Immunol. 2015 Aug;136(2):476-9.e6
pubmed: 25981738
Curr Allergy Asthma Rep. 2018 Feb 22;18(3):19
pubmed: 29470720
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Mol Med. 2022 Mar 26;28(1):38
pubmed: 35346031
Genet Med. 2022 Jan;24(1):192-200
pubmed: 34906498
Genet Med. 2017 Feb;19(2):209-214
pubmed: 27441994
J Allergy Clin Immunol. 2016 Jan;137(1):3-17
pubmed: 26768758
Nature. 2020 Jul;583(7814):90-95
pubmed: 32499645
Int Arch Allergy Immunol. 2022;183(3):337-349
pubmed: 34619682
Eur J Hum Genet. 2021 Sep;29(9):1337-1347
pubmed: 34075210
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
J Family Med Prim Care. 2017 Oct-Dec;6(4):709-711
pubmed: 29564248
Genes Immun. 2015 Dec;16(8):552-66
pubmed: 26513235
Bioinformatics. 2019 Jul 1;35(13):2315-2317
pubmed: 30475984
Hum Mutat. 2019 Oct;40(10):1797-1812
pubmed: 31231902
Front Immunol. 2015 Apr 01;6:142
pubmed: 25883595
J Mol Diagn. 2019 Jan;21(1):38-48
pubmed: 30577886
Curr Opin Immunol. 2017 Oct;48:122-133
pubmed: 28992464
J Autoimmun. 2019 May;99:52-72
pubmed: 30795880
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Genet Med. 2019 Jun;21(6):1267-1270
pubmed: 31015575
N Engl J Med. 2019 Jun 20;380(25):2478-2480
pubmed: 31216405
Bioinformatics. 2016 Apr 15;32(8):1220-2
pubmed: 26647377
Nat Immunol. 2018 Dec;19(12):1415-1426
pubmed: 30349037
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Gene. 2018 Jan 30;641:279-286
pubmed: 29080837
Genet Med. 2020 Jan;22(1):85-94
pubmed: 31358947
J Clin Immunol. 2019 Aug;39(6):577-591
pubmed: 31250335
Autoimmun Rev. 2018 Oct;17(10):1028-1039
pubmed: 30107266
Nat Rev Genet. 2021 Mar;22(3):137-153
pubmed: 33277640
Scand J Immunol. 2017 Jun;85(6):450-461
pubmed: 28370285
Genome Med. 2019 Dec 17;11(1):83
pubmed: 31847883
Genet Med. 2019 Jan;21(1):161-172
pubmed: 29907797
Eur J Hum Genet. 2018 May;26(5):740-744
pubmed: 29453418
Clin Rev Allergy Immunol. 2020 Aug;59(1):109-121
pubmed: 31720921